A growing number of studies suggests that IKZF1 dysfunction may also lead to activation of the PI3K/AKT/mTOR pathway, and this, in turn, promotes resistance to glucocorticoids, which are essential drugs in the treatment of patients with ALL [206,207]. This evidence concerns the gene MTOR and acute lymphoblastic leukemia.